Differentiated Thyroid Carcinoma

• FDA approval · 2014-03-21
  FDA Approved: THYROGEN — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for THYROGEN (thyrotropin alfa) submitted by Genzyme Corporation.

• CLINICAL_TRIALS trial_result · 2013-10-01
  Clinical Trial Update: P53 in Differentiated Thyroid Cancer

  This update reports a completed clinical trial investigating the role of p53 in differentiated thyroid carcinoma.

• FDA approval · 2013-05-07
  FDA Approved: THYROGEN — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for THYROGEN (thyrotropin alfa) from Genzyme Corporation.

• CLINICAL_TRIALS trial_result · 2012-12-27
  Clinical Trial Update: Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer [Phase 2]

  Phase 2 trial evaluating whether adding lithium carbonate to low-dose radioiodine therapy improves outcomes in early thyroid cancer.

• FDA approval · 2012-08-24
  FDA Approved: NEXAVAR — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

  FDA approved a supplemental application for Nexavar (sorafenib) submitted by Bayer HealthCare Pharmaceuticals Inc.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2012-07-27
  FDA Approved: THYROGEN — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for THYROGEN (thyrotropin alfa) from Genzyme Corporation.

• CLINICAL_TRIALS research · 2011-06-16
  Clinical Trial Update: Diagnostic Utility of [18F]-FDG-PET/CT and [124I]-PET/CT for Detection of Recurrence in Differentiated Thyroid Carcinoma

  This document reports a clinical trial evaluating the diagnostic usefulness of [18F]-FDG-PET/CT and [124I]-PET/CT for detecting recurrence i…

• FDA label_change · 2008-08-12
  FDA Approved: THYROGEN — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental labeling for THYROGEN (thyrotropin alfa) by Genzyme Corporation, expanding/modifying its indications for use in …

• FDA label_change · 2008-01-17
  FDA Approved: HICON — Supplemental Application (Jubilant DraxImage Inc., dba Jubilant Radiopharma)

  FDA approved a supplemental application for HICON (Sodium Iodide I-131) from Jubilant Radiopharma, updating its labeling.

• FDA approval · 2007-12-14
  FDA Approved: THYROGEN — Supplemental Application (Genzyme Corporation)

  FDA approved a supplemental application for THYROGEN (thyrotropin alfa) from Genzyme Corporation.

• FDA approval · 2007-04-18
  FDA Approved: HICON — Supplemental Application (Jubilant DraxImage Inc., dba Jubilant Radiopharma)

  The FDA approved a supplemental application for HICON (sodium iodide I-131) submitted by Jubilant DraxImage Inc., dba Jubilant Radiopharma.

• CLINICAL_TRIALS trial_result · 2007-02-28
  Clinical Trial Update: OnT4-Thyroglobulin Assay Before rhTSH-Aided Radioiodine Ablation

  This trial update indicates completion of a study evaluating the OnT4-Thyroglobulin assay used before rhTSH-aided radioiodine ablation in di…

• CLINICAL_TRIALS trial_result · 2006-05-09
  Clinical Trial Update: Multicenter Study Differentiated Thyroid Carcinoma [Phase 3]

  A multicenter Phase 3 trial in differentiated thyroid carcinoma, sponsored by University Hospital Muenster, has completed.